These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 21183005

  • 1. Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.
    Pritchard L, Baker C, Leggett J, Sehdev P, Brown A, Bayley KB.
    Am J Med; 2010 Dec; 123(12):1143-9. PubMed ID: 21183005
    [Abstract] [Full Text] [Related]

  • 2. Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database.
    Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, Ford KD, Zervos MJ, Ramirez JA, Kett DH, Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group.
    Clin Ther; 2012 Jan; 34(1):149-57. PubMed ID: 22284995
    [Abstract] [Full Text] [Related]

  • 3. Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children.
    McKamy S, Hernandez E, Jahng M, Moriwaki T, Deveikis A, Le J.
    J Pediatr; 2011 Mar; 158(3):422-6. PubMed ID: 20888013
    [Abstract] [Full Text] [Related]

  • 4. The Relationship of nephrotoxicity to vancomycin trough serum concentrations in a veteran's population: a retrospective analysis.
    Horey A, Mergenhagen KA, Mattappallil A.
    Ann Pharmacother; 2012 Nov; 46(11):1477-83. PubMed ID: 23073306
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections.
    Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME.
    Expert Opin Drug Saf; 2010 Jan; 9(1):9-14. PubMed ID: 20021290
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
    Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL.
    Clin Infect Dis; 2009 Aug 15; 49(4):507-14. PubMed ID: 19586413
    [Abstract] [Full Text] [Related]

  • 8. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy.
    Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ, Hetsko CM.
    Pharmacotherapy; 1990 Aug 15; 10(6):378-82. PubMed ID: 2287556
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
    Kullar R, Leonard SN, Davis SL, Delgado G, Pogue JM, Wahby KA, Falcione B, Rybak MJ.
    Pharmacotherapy; 2011 May 15; 31(5):441-8. PubMed ID: 21923425
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Trough concentration over 12.1 mg/L is a major risk factor of vancomycin-related nephrotoxicity in patients with therapeutic drug monitoring.
    Han HK, An H, Shin KH, Shin D, Lee SH, Kim JH, Cho SH, Kang HR, Jang IJ, Yu KS, Lim KS.
    Ther Drug Monit; 2014 Oct 15; 36(5):606-11. PubMed ID: 24577126
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy.
    Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA.
    J Antimicrob Chemother; 2008 Jul 15; 62(1):168-71. PubMed ID: 18334494
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Impact of pharmacist intervention on preventing nephrotoxicity from vancomycin.
    Masuda N, Maiguma T, Komoto A, Haruki Y, Sugiyama T, Kondo S, Teshima D.
    Int J Clin Pharmacol Ther; 2015 Apr 15; 53(4):284-91. PubMed ID: 25740266
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD, Drew RH.
    Pharmacotherapy; 2014 Jul 15; 34(7):670-6. PubMed ID: 24855041
    [Abstract] [Full Text] [Related]

  • 18. [Efficacy and nephrotoxicity of vancomycin in the treatment of Gram positive infections].
    Du B, Chen DC, Liu DW.
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Jan 15; 15(1):32-4. PubMed ID: 12852813
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
    Fernández de Gatta MD, Calvo MV, Hernández JM, Caballero D, San Miguel JF, Domínguez-Gil A.
    Clin Pharmacol Ther; 1996 Sep 15; 60(3):332-40. PubMed ID: 8841156
    [Abstract] [Full Text] [Related]

  • 20. High-dose intravenous vancomycin therapy and the risk of nephrotoxicity.
    Rostas SE, Kubiak DW, Calderwood MS.
    Clin Ther; 2014 Jul 01; 36(7):1098-101. PubMed ID: 24931573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.